Outcomes following indomethacin prophylaxis in extremely preterm infants in an all-referral NICU

Journal of Perinatology

Volumn 37, Issue 8, 2017, Pages 932-937

  Nelin, T D ^a   Pena, E ^b,c   Giacomazzi, T ^b   Lee, S ^b   Logan, J W ^b,c   Moallem, M ^b,c   Bapat, R ^b,c   Shepherd, E G ^b,c   Nelin, L D ^a,b,c  

^a THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; BIRTH WEIGHT; BRAIN HEMORRHAGE; CHEMOPROPHYLAXIS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; EXTREME PREMATURITY; GESTATIONAL AGE; HUMAN; INFANT; INFANT MORTALITY; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MORTALITY RATE; NEONATAL INTENSIVE CARE UNIT; OBSERVATIONAL STUDY; PATENT DUCTUS ARTERIOSUS; PREMATURITY; RISK REDUCTION; TREATMENT OUTCOME; BRAIN VENTRICLE HEMORRHAGE; FEMALE; MALE; MORTALITY; NEWBORN; PROCEDURES; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIRTH WEIGHT; BRONCHOPULMONARY DYSPLASIA; CEREBRAL INTRAVENTRICULAR HEMORRHAGE; CHEMOPREVENTION; DUCTUS ARTERIOSUS, PATENT; FEMALE; GESTATIONAL AGE; HUMANS; INDOMETHACIN; INFANT; INFANT MORTALITY; INFANT, EXTREMELY PREMATURE; INFANT, NEWBORN; INTENSIVE CARE UNITS, NEONATAL; MALE; TREATMENT OUTCOME; UNITED STATES;

EID: 85028620337     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/jp.2017.71     Document Type: Article

References (30)

1. Patel RM, Kandefer S, Walsh MC. Causes and timing of death in extremely premature infants from 2000 through 2011. N Engl J Med 2015; 372: 331-340.
2. Tyson JE, Parikh NA, Langer J, Green C, Higgins RD. Intensive care for extreme prematurity - moving beyond gestational age. N Engl J Med 2008; 358: 1672-1681.
3. Costeloe KL, Hennessy EM, Haider S, Stacey F, Marlow N, Draper ES. Short term outcomes after extreme preterm birth in England: comparison of two birth cohorts in 1995 and 2006 (the EPICure studies). BMJ 2012; 345: e7976.
4. Vento M, Cheung PY, Aguary M. The first golden minutes of the extremely-low-gestational-age neonate: a gentle approach. Neonatology 2009; 95(4): 286-298.
5. Arzuaga BH, Meadow W. National variability in neonatal resuscitation practices at the limit of viability. Am J Perinatol 2014; 31(6): 521-528.
6. Lorenz JM. The outcome of extreme prematurity. Semin Perinatol 2001; 25(5): 348-359.
7. Volpe JJ. Impaired neurodevelopmental outcome after mild germinal matrix-intraventricular hemorrhage. Pediatrics 2015; 136(6): 1185-1187.
8. Clyman RI, Couto J, Murphy GM. Patent ductus arteriosus: are current neonatal treatment options better or worse than no treatment at all? Semin Perinatol 2012; 36(2): 123-129.
9. Schneider DJ, Moore JW. Patent ductus arteriosus. Circulation 2006; 114(17): 1873-1882.
10. Patel RM, Kandefer S, Walsh MC, Bell EF, Carlo WA, Laptook AR et al. Causes and timing of death in extremely premature infants from 2000 through 2011. N Engl J Med 2015; 372: 331-340.
11. Horbar JD, Carpenter JH, Badger GJ, Kenny MJ, Soll RF, Morrow KA et al. Mortality and neonatal morbidity among infants 501 to 1500 grams from 2000 to 2009. Pediatrics 2012; 129: 1019-1026.
12. Ment LR, Ehrenkranz RA, Duncan CC, Scott DT, Taylor KJW, Katz KH et al. Low-dose indomethacin and prevention of intraventricular hemorrhage: a multicenter randomized trial. Pediatrics 1994; 93(4): 543-550.
13. Ment LR, Oh W, Ehrenkranz RA, Phillip AGS, Vohr B, Allan W et al. Low-dose indomethacin therapy and extension of intraventricular hemorrhage: a multicenter randomized trial. J Pediatr 1994; 124(6): 951-955.
14. Schmidt B, Davis P, Moddemann D, Ohlsson A, Roberts RS, Saigal S et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med 2001; 344: 1966-1972.
15. Narayanan M, Cooper B, Weiss H, Clyman RI. Prophylactic indomethacin: factors determining permanent ductus arteriosus closure. Pediatrics 2000; 136(3): 330-337.
16. Moorehead PA, Martin EM, Shepherd EG, Parikh NA, Reagan PB, Gardner W et al. Factors associated with survival of o27 week infants in an all-referral neonatal intensive care unit. J Neonatal Perinatal Med 2012; 5: 105-111.
17. Nankervis CA, Martin EM, Crane ML, Samson KS, Welty SE, Nelin LD. Implementation of a multidisciplinary guideline-driven approach to the care of the extremely premature infant improved hospital outcomes. Acta Paediatr 2010; 99: 188-193.
18. Bartman T, Bapat R, Martin EM, Shepherd EG, Nelin LD, Reber KM. Apgar Score at 5 minutes is associated with mortality in extremely preterm infants even after transfer to an all referral NICU. Am J Perinatol 2015; 32: 1268-1272.
19. Fowlie PW, Davis PG, McGuire W. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev 2010; 7: CD000174.
20. Fowlie PW, Davis PG. Prophylactic indomethacin for preterm infants: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed 2003; 88: F464-F466.
21. Couser RJ, Hoekstra RE, Berrara TB. Neurodevelopmental follow-up at 36 months' corrected age of preterm infants treated with prophylactic indomethacin. Arch Pediatr Adolesc Med 2000; 154(6): 598-602.
22. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A et al. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med 2007; 357: 1893-1902.
23. Darlow BA, Graham PJ. Vitamin A supplementation to prevent mortality and short and long-term morbidity in very low birthweight infants. Cochrane Database Syst Rev 2007; 17(4): CD000501.
24. Doyle LW, Ehrenkranz RA, Halliday HL. Dexamethasone treatment in the first week of life for preventing bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 2010; 98(3): 217-224.
25. Lodha A, Seshia M, McMillan DD, Barrington K, Yang J, Lee SK et al. Association of early caffeine administration and neonatal outcomes in very preterm neonates. JAMA Pediatr 2015; 169(1): 33-38.
26. Taha D, Kirkby S, Nawab U. Early caffeine therapy for prevention of bronchopulmonary dysplasia in preterm infants. J Matern Fetal Neonatal Med 2014; 27(16): 1698-1702.
27. Clyman RI, Saha S, Jobe A, Oh W. Indomethacin prophylaxis for preterm infants: the impact of two multicentered randomized controlled trials on clinical practice. J Pediatr 2007; 150(1): 46-50.
28. Guillén U, De Mauro S, Ma L, Zupancic J, Roberts R, Schmidt B et al. Relationship between attrition and neurodevelopmental impairment rates in extremely preterm infants at 18 to 24 months: a systematic review. Arch Pediatr Adolesc Med 2012; 166(2): 178-184.
29. Horbar JD, Edwards EM, Greenberg LT, Morrow KA, Soll RF, Buus-Frank ME et al. Variation in performance of neonatal intensive care units in the United States. JAMA Pediatr 2017; 171(3): e164396.
30. Rozé JC, Cambonie G, Marchand-Martin L, Gournay V, Durrmeyer X, Durox M et al. Association between early screening for patent ductus arteriosus and in-hospital mortality among extremely preterm infants. JAMA 2015; 313(24): 2441-2448.